SELLAS LIFE SCIENCES GROUP I(NASDAQ:SLS) stock News

SLS Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill

SELLAS Life Sciences Group Inc (NASDAQ:SLS) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Amid Revenue Challenges

2 days ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

7 days ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

14 days ago - By: Zacks Investment Research

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

a month ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

a month ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

2 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

2 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

2 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

3 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

3 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

3 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

4 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

4 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

5 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

6 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

7 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

7 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

7 months ago - By: Benzinga - Mentions: GILD VRTX JNJ TGTX ...

8 Health Care Stocks Whale Activity In Today's Session

7 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Announces Key Business Objectives for 2025

7 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

8 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

8 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

9 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

9 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

9 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

10 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS LIFE SCIENCES GROUP I (SLS) Stock News

SLS Latest News, Press Relases and Analysis